Orexo

Orexo
Public
Traded as Nasdaq Stockholm: ORX
OTCQX: ORXOY
Industry Pharmaceutical
Founded 1995 (1995)
Headquarters Uppsala, Sweden
Area served
 Worldwide
Key people
 Nikolaj Sørensen
(CEO)
Products See list
Revenue Increase SEK 429.4 million (2013)[1]
Decrease SEK 154.9 million (2013)[1]
Number of employees
 108 (2013) [1]
Website Orexo.com
Footnotes / references
Employee and financial data as of 2014

Orexo is a pharmaceutical company based in Uppsala, Sweden initially financed with venture capital provided by HealthCap.

The company was founded in 1995 and their first product Diabact UBT, a breath test for diagnosing the causative agent of stomach ulcers (Helicobacter pylori), was introduced in 2000.[2] In 2003, the company adopted the name Orexo and in 2005 the company was listed on the Stockholm Stock Exchange.[2]

Products

  • Abstral, for the treatment of breakthrough cancer pain. It was approved in 2008 in Europe and for marketing in United States by the FDA in 2011.[2]
  • Edluar, for the treatment of short-term insomnia. FDA approved in 2009.[2]
  • Zubsolv a dissolvable tablet which combines the drugs buprenorphine and naloxone and treats opioid dependency and addiction.[3] FDA approved in July 2013.[3] Launched in the United States in September 2013 [4]

References

  1. 1 2 3 "2013 Annual Report". Orexo. 2014. Retrieved October 12, 2014.
  2. 1 2 3 4 "History". Orexo. Retrieved July 5, 2013.
  3. 1 2 Toni Clarke (July 4, 2013). "U.S. FDA approves Orexo drug to treat opioid addiction". Reuters. Retrieved July 5, 2013.
  4. ↑ Press releases - Orexo
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.